Purchase XYPHOID INJECTION, containing Ceftriaxone, to combat gram-negative bacteria in animals. Effective treatment for hemorrhagic septicemia, broncho-pneumonia, and more.

Guaranteed Safe Checkout
XYPHOID INJECTION – Ceftriaxone Antibiotic for Effective Gram-Negative Bacteria Control
₹210 – ₹245
Please upload your valid prescription during checkout to proceed with this order.
Description
Introducing “XYPHOID INJECTION” – your powerful solution for eradicating gram-negative bacteria in animals swiftly and effectively. This injection, packed with Ceftriaxone, targets and eliminates various bacterial infections, ensuring the health and well-being of your animals.
Composition:
Each vial of XYPHOID INJECTION contains:
- Ceftriaxone sodium IP (sterile) equivalent to Ceftriaxone: 3 g or 4 g
Indications:
- Hemorrhagic Septicemia (HS): Treats acute bacterial septicemia in animals.
- Broncho-Pneumonia: Effective against bacterial infections in the lungs.
- Nephritis & Cystitis: Addresses kidney and bladder infections.
- Metritis & Pyometra: Treats infections in the uterus.
- Actinobacillosis: Controls bacterial infections in cattle.
- Mastitis: Combats bacterial infections in the udder.
- Bacterial Meningitis: Treats inflammation of the brain caused by bacteria.
- Pre & Post-Operative Treatment: Prevents and manages bacterial infections before and after surgeries.
- Endometritis: Addresses inflammation of the uterine lining.
Dosage:
- Administer 5-10 mg/kg of body weight.
Administration: For IM/IV use only.
Packing/Presentation: XYPHOID INJECTION is available in 3 g and 4 g vials, ensuring convenient administration and storage.
With XYPHOID INJECTION, effectively combat gram-negative bacterial infections in your animals, ensuring their health and vitality.
Additional information
PACK |
3 GM ,4 GM |
---|
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.